Massive registry study aims to unlock secrets of rare thyroid cancer
NCT ID NCT04216732
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study uses a large registry of 2030 people with medullary thyroid cancer to track how the disease develops and spreads. Researchers will collect medical records, genetic data, and patient surveys to better understand the cancer's natural history. The goal is to improve how advanced medullary thyroid cancer is managed, but no new treatments are being tested.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better understand how medullary thyroid cancer progresses, potentially leading to improved treatment strategies and patient care.
- What could go wrong
- This is an observational study, not a treatment trial. It collects data only and does not test any new drug or therapy, so it cannot directly improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,030 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2020
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients diagnosed with MTC including advanced phase MTC determined by clinical team
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aims 1 and 2: A diagnosis of MTC * Aims 1 and 2: A registrant in the Medullary Thyroid Cancer Registry (MTCR). Patients of all disease phases will be eligible for enrollment * Aim 3: A diagnosis of advanced phase (red or gray) MTC as determined by clinical team * Aim 3: A current registrant in the MTCR
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced thyroid gland medullary carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive antibody combo targets thyroid cancer
- Thyroid surgery under the microscope: what 3,000 real operations reveal
- Massive database study probes link between popular diabetes drugs and rare thyroid cancer
- New imaging agent could improve detection of rare cancers
- New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
- New radioactive therapy targets hard-to-treat thyroid cancer